ArticleGenetics and molecular biology2026
All you need is fungi: Exploring secondary metabolites as a source of novel amoebicidal agents.
Article in Genetics and molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Free-living amoebae (FLAs) of the genus Acanthamoeba are opportunistic protozoa found in diverse environments. They can cause granulomatous amoebic encephalitis, especially in immunocompromised individuals, and Acanthamoeba keratitis, a painful corneal infection frequently associated with contact lens wearers. Effective treatments for Acanthamoeba infections are limited, with nitroimidazoles as the main pharmacological option, a class of drugs generally associated with side effects. Given the limited availability of vaccines and the low efficacy of existing drugs, the search for new therapeutic strategies is crucial. Interactions between fungi and predatory amoebae have driven the production of defensive fungal secondary metabolites (SMs) with potent amoebicidal properties. The evolutionary pressure from predatory amoebae has equipped fungi, particularly from the Aspergillus, Beauveria, and Fusarium genera, to produce a wide variety of defensive bioactive compounds, including non-ribosomal peptides, polyketides, and terpenes. Some examples of fungal-derived SMs include cephalosporins, mycophenolic acid, griseofulvin, pleuromutilins and lovastatin. Furthermore, gliotoxin and trypacidin from Aspergillus fumigatus exhibit amoebicidal activity by impairing key protozoan functions like phagocytosis. These findings highlight the potential of fungal SMs as novel amoebicidal agents. Exploring fungal biodiversity could lead to the discovery of innovative medicines, harnessing natural compounds to combat infections caused by Acanthamoeba species and other protozoan pathogens.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.